Shattuck Labs, Inc. Other Accrued Liabilities, Current
Shattuck Labs, Inc. (STTK) had Other Accrued Liabilities, Current of $351.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Payables and Accruals
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Other Accrued Liabilities, Current $351.00K.
- 2026-03-31: Other Accrued Liabilities, Current $335.00K.
- 2025-12-31: Other Accrued Liabilities, Current $236.00K.
- 2025-09-30: Other Accrued Liabilities, Current $213.00K.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $351.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $335.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $236.00K 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $213.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $243.00K 10-Q · filed 2025-08-14 | |
| 2024-12-31 | $410.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $235.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $488.00K 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $363.00K 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $1.04M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $224.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $184.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.63M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $471.00K 10-K · filed 2024-02-29 | $1.17M 10-K · filed 2023-02-23 |
| 2022-09-30 | $1.29M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $2.45M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $922.00K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $1.00M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $638.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.25M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $569.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $419.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $791.00K 10-Q · filed 2020-11-13 | |
| 2019-12-31 | $425.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |